Significant results: the study revealed - how the weight loss injection affects children

A new study published in the NEJM and presented at ObesityWeek 2026 reveals that the weight loss injection Wegovy is effective in reducing BMI in children aged 6 to 12 with obesity. Nearly 80% of treated children reduced at least 10% of their body mass index, with no safety concerns regarding growth or sexual development.

Results from a new study presented at the ObesityWeek 2026 conference and published in the New England Journal of Medicine show high efficacy of the weight loss injection Wegovy (semaglutide) in children aged 6 to 12 suffering from obesity. In the phase three trial, STEP Young, it was found that nearly 80% of children treated with the drug reduced at least 10% of their body mass index (BMI), compared to no children in the placebo group. The average BMI reduction in the treatment group was 17.4% after 68 weeks, while the placebo group saw an increase of 2.2%. Additionally, 40.4% of children in the Wegovy group were no longer classified as obese by the end of the study. The safety profile was consistent with previous studies, and no concerns were identified regarding growth or sexual development. The lead researcher, Dr. Ania Jastreboff from Yale University, noted that the treatment may change the trajectory of the children's health development.

Significant results: the study revealed - how the weight loss injection affects children